Plerixafor (Mozobil®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000394
English
Authors' recommendations:
Plerixafor (Mozobil®) is recommended as an option for restricted use within NHS Wales in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly. Plerixafor (Mozobil®) should be restricted for use specifically in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM) who have already failed one complete mobilisation attempt. AWMSG is of the opinion that plerixafor (Mozobil®) is not suitable for shared care within NHS Wales.
Details
Project Status:
Completed
Year Published:
2010
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=156344&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Heterocyclic Compounds
- Lymphoma
- Multiple Myeloma
- Granulocyte Colony-Stimulating Factor
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.